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The evidence linking low serum sodium levels with the risk of mortality in peritoneal dialysis (PD) patients 
is controversial. Considering the different mechanisms contributing to hyponatremia in these patients, it is 




Following a retrospective, observational design, we analyzed the association between hyponatremia and 
mortality in 748 patients incident on PD. We applied multivariate strategies of analysis, with the main 
objective of identifying subgroups of patients in whom hyponatremia could sustain different degrees of 
association with mortality (main outcome variable). For this purpose, we performed preliminary analyses to: 
(1) disclose predictors of serum sodium levels before and after (mean of first 3 months) initiation of PD (main 
study variable) and (2) investigate the overall prognostic significance of hyponatremia, in our patients. 
 
 Results: 
Comorbidity, hypoalbuminemia, and lower glomerular filtration rate (GFR) were main predictors of 
hyponatremia. Use of icodextrin was another inverse correlate of serum sodium, and the only consistent 
predictor of a decline of natremia, once PD was started. Multivariate analysis confirmed early hyponatremia 
as an independent marker of survival. However, stratified analyses showed that this association was most 
apparent in specific subsets, namely, hypoalbuminemic, more anemic patients with higher baseline levels of 
GFR and C-reactive protein and faster peritoneal solute transport rates. Other factors potentially reinforcing 
the prognostic significance of hyponatremia included lower lean body mass levels, nonprescription of renin-
angiotensin-aldosterone system antagonists, and use of icodextrin-based PD solution. On the contrary, 
baseline overhydration or categorization by classic predictors of mortality (age, comorbidity, diabetes) did not 
appear to influence the risk pattern associated with lower serum sodium levels.  
 
Conclusions:   
 
Our results suggest that hyponatremia performs as a consistent correlate of the risk of mortality 
mainly in PD patients manifesting direct or indirect signs of  inflammation and wasting, while this association 
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Introduction 
Patients with chronic kidney disease (CKD) present markedly increased rates of  mortality, 
related both to associated clinical conditions (usually assessed from age, presence of diabetes, and 
comorbidity scores) and to the adverse consequences intrinsic to CKD and its management [1]. 
The complex pathogenesis of CKD-related mortality complicates the generation of models 
predicting this outcome, fed by the countless array of potential markers reported in the literature 
[2]. Fluid and electrolyte disorders are extremely frequent in CKD, and their influence on the 
outcome of these patients has been extensively investigated [3, 4]. In particular, the correlation 
between disorders of sodium concentration (mainly hyponatremia, but also hypernatremia) and 
mortality at different stages of CKD has been a subject of great interest [5]. A link between these 2 
complications is generally accepted, although it is often unclear in which proportion hyponatremia 
is a risk marker and a cause of mortality, in this setting. 
 
In the particular case of patients undergoing chronic peritoneal dialysis (PD), the evidence 
linking hyponatremia and mortality is limited and controversial, with some studies reporting a 
significant association [6–8], which has not been observed by others [9, 10]. Admitting that there 
are different potential mechanisms leading to hyponatremia in these individuals [11, 12], it is 
conceivable that at least part of these discrepancies may be related to different characteristics of 
PD patients and practices. This hypothesis suggests the convenience of identifying clinical subsets 
in which serum sodium could perform more or less efficiently as a risk marker of PD-related 
mortality. 
 
We have undertaken a retrospective, observational study of a relatively large population of 
patients incident in PD therapy, with the primary objective of identifying specific clinical subsets 
modulating the association between early hyponatremia and mortality during follow-up. Our main 
interest was to clarify the relative role of 3 main mechanisms of hyponatremia in PD 
patients, namely overhydration, wasting/inflammatory states, and the conditions of drug 
and dialysis prescription. To accomplish these goals, we performed preliminary analyses 
to (1) disclose clinical predictors of serum sodium levels before and after initiation of PD 
and (2) appraise the overall correlation between serum sodium .levels and survival, in our 
setting (secondary objectives). 
Methods 
General Design 
Following a retrospective, observational design, we analyzed the prognostic significances of 
serum sodium levels preceding initiation of PD (preNa), mean of values recorded during the first 3 
months of PD therapy (mean serum sodium [mNa]), and changes in sodium levels between the 
aforementioned periods. Our main objective was to disclose particular subsets in which mNa could 
bear a differentiated prognostic value. The main outcome variable was mortality during follow-up 
on PD. The study setting was a tertiary university hospital, sustaining a mean prevalent population 
on PD of 120 patients, and a mean incidence of 35 patients per year. We applied multivariate 
strategies of analysis to control for other variables with an influence on the main outcome. 
Secondarily, we explored the clinical spectrum of predictors of preNa, mNa, and changes in 
sodium levels. 
 
The study complied with the principles of the Declaration of Helsinki and the ethical requirements 
of our center for observational, retrospective studies. Oral informed consent was obtained from all 
patients available at the time of initiation of the study. 
Population 
For this study, we selected patients initiating PD therapy between January 1991 and June 2018, 
fulfilling the following inclusion/exclusion criteria: 
−− Adult patients (> 18 years of age) 
−− Incident on PD 
−− Patients alive after 90 days on PD therapy 
−− At least 1 estimation of serum sodium levels in the 2 months preceding PD start available 
−− At least 1 estimation of serum sodium levels during the first 3 months after inception of PD      
available 
−− Information on preexisting comorbidity, residual kidney function  (RKF) an drug, and dialysis 
prescription at the start of PD  available 
−− Oral informed consent provided (only patients active at the  initiation of the study). 
Study Variables 
mNa level was the main study variable and was estimated as the mean of available serum Na 
levels recorded during the first 3 months after initiation of PD (median 3 estimations, range 1–5). 
preNa (last Na value before initiation of PD) and changes in sodium levels after inception of PD 
(difference mNa – preNa) were secondary study variables. Serum sodium levels were estimated 
using the same ionselective electrode method during all the study period. Mortality was the main 
outcome variable. By definition, all patients had a minimal survival of 3 months on PD. Patients 
were censored in case of kidney transplant, change to hemodialysis therapy, or loss to follow-up. 
 
Control variables included: dialysis vintage (PD started before/after the end of 2004), age, gender, 
comorbidity (Charlson’s comorbidity score), history of heart disease, diabetes, malnutrition 
(standard subjective global assessment), body mass index (BMI; weight/height2), glomerular 
filtration rate (GFR; mean of the renal clearances of urea and creatinine), plasma albumin, serum 
C-reactive protein (CRP; immunoturbidimetry), blood hemoglobin, D/P creatinine ratio at 240 min 
during the baseline peritoneal equilibration test (PET; D/Pcrea), standardized ultrafiltration during 
the baseline PET (available in only 241 patients with a baseline PET performed with 3,86% 
glucose-based dialysate), modality of PD, use of  icodextrin for the long dwell, and treatment with 
loop diuretics (we applied an arbitrary equivalence of 10 mg of torasemide = 40 mg of  
furosemide), renin-angiotensin-aldosterone system (RAAS) antagonists, psychotropic drugs 
(antidepressives and/or antipsychotics), and immunosuppressives (including steroids, active during 
the preceding year and/or at the start of PD therapy). In a limited number of patients (those starting 
PD after early 2010; n = 180), we scrutinized body composition at the time of the baseline PET, 
using a bioimpedance analysis device (BCM, Fresenius, Germany). We recorded lean body mass 
and fat mass (normalized for body surface), total overhydration, and ratio of extracellular to 
intracellular water. All the control variables were recorded at baseline, except PET and 
bioimpedance analysis (performed 4–6 weeks after initiation of PD), and treatment with 
icodextrin, loop diuretics, RAAS antagonists, and psychotropic drugs, for which we requested an 
active prescription during at least 2 of the first 3 months on PD. 
Strategy of Analysis 
Our strategy of analysis followed 3 steps: 
 
1. We first investigated predictors of preNa, mNa, and changes in sodium levels after PD was 
started. For this purpose, we applied univariate (Spearman’s correlation coefficient, Student t test 
and ANOVA) and multivariate (stepwise multiple regression) strategies. For multivariate analyses, 
we explored only first-order interaction terms. Diabetes and heart disease were explored either as 
independent variables or included in the global Charlson’s score. Separate analyses were generated 
for variables available in a limited number of cases (body composition and ultrafiltration during 
the baseline PET). 
 
2. Second, we performed an exploratory analysis of variables predicting mortality, searching for an 
adjusted effect of the main study variables. We first identified univariate predictors of mortality 
(Kaplan-Meier, log rank test), generating a reference multivariate model (Cox regression), oriented 
to estimate an adjusted association between preNa, mNa, and changes in sodium levels, on one 
side, and mortality, on the other. Again, only first-order interaction terms were explored, and 
stratified analyses were generated for significant terms. Similarly to the previous step, we 
generated specific models for variables available in a limited number of cases. 
 
3. Finally, we explored control variables with a clinical interest, but without a demonstrated 
independent association with patient survival, searching for specific subsets in which mNa levels 
could present a differentiated association with mortality. For this purpose, we used, again, 
stratified analyses, obtaining adjusted estimations (Cox) of the association between mNA and 
mortality in each explored subset. 
 
We categorized numerical variables according to their median values, except in 2 specific 
cases (plasma albumin, GFR), in which we decided to fit categorization to clinical significance. 
We used SPSS 19.0 software for data management and analysis. 
Results 
Overview 
Eight hundred and seventy-seven patients started PD during the study period. The main causes 
of exclusion from the study were insufficient follow-up on PD (n = 61) and inadequate data on 
GFR (n = 29) and/or serum sodium levels before/after initiation of therapy (n = 23). Overall, 748 
patients were included in the analysis. The main characteristics of the study population at initiation 
of PD are displayed in Table 1. The distribution of causes for CKD was standard. Table 2 shows 
plasma sodium levels before and after PD inception. Only 24 patients (3.2%) presented mNa levels 
> 143 mM/L, and only 4 (0.5%) had a mNa > 145 mM/L; consequently, no further attention was 
dedicated to hypernatremia. Followup on PD was 31.6 ± 25.7 months. At the end of followup, 
only 77 patients were active on PD, while 346 patients (46.3%) had died, 209 (27.9%) had 
undergone a kidney transplant, 94 (12.6%) had been switched to hemodialysis, 5 (0.7%) 
suspended PD after partial recovery of kidney function, and 17 (2.3%) were lost to follow-up. 
Death was mainly due to cardiovascular events (n = 159), infections (n = 84) and dialysis 
withdrawal (n = 42). 
Correlates of Plasma Sodium Levels 
Multivariate analysis disclosed comorbidity (Charlson’s score), hypoalbuminemia, lower GFR, 
and a lower dose of loop diuretics as independent predictors of lower preNa levels (Table 3). 
Diabetes and a history of heart failure performed as convenient surrogates of Charlson’s score, at 
the time of modeling preNa (Table 3). 
 
The primary multivariate model for prediction of mNa identified Charlson’s score, 
hypoalbuminemia, lower GFR, a more severe degree of anemia, and use of icodextrin for the long 
dwell as independent predictors of lower mNa levels (Table 4). Again, inclusion of diabetes and 
heart failure, rather than Charlson’s score, improved marginally the quality of the model. 
 
Older patients and those on loop diuretics tended to experience a decrease in serum sodium 
after initiation of PD but, in practical terms, icodextrin-based PD was the only consistent predictor 
of such an evolution (Table 5). 
Correlation between Serum Sodium Levels and Mortality: General Model 
Table 6 and Figure 1 display significant univariate predictors of mortality. The best 
multivariate model (Table 6) included well-known markers including age, Charlson’s score, 
plasma albumin (or serum CRP), blood hemoglobin, GFR, and D/Pcrea at the start of PD. In 
addition, both preNa and mNa performed as independent predictors of mortality during follow-up, 
while the time course of serum sodium after initiation of PD did not show such an effect. Plasma 
albumin, serum CRP, blood hemoglobin, and GFR presented significant interaction with mNa 
levels, while D/Pcrea was close to significance (Table 6). The results of the subsequent stratified 
analyses will be presented in the next paragraph. 
 
In separate models, ultrafiltration during the baseline PET did not perform as an independent 
predictor of mortality. Regarding body composition analysis, we observed only a minor, 
nonsignificant trend (p = 0.089) to an inverse association between lean body mass and the main 
study outcome. 
Table 1. Study population and baseline parameters 
 
Multifrequency BIA (n = 180). Comparisons by ANOVA and χ2 distribution. BMI, body mass index; BIA, bioimpedance analysis; ECW/ICW, extracellular/intracellular water; GFR, glomerular filtration rate; CRP, C-reactive 
protein; PET, peritoneal equilibration test; UF, ultrafiltration; PD, peritoneal dialysis; CAPD, continuous ambulatory PD; APD, automated PD; RAAS, renin-angiotensin-aldosterone system.
    Table 2. Plasma sodium levels 
 
Before dialysis, mM/L, mean (SD); IQR                                137.75 (4.40); 135–140 
First after initiation of PD, mM/L, mean (SD); IQR        137.74 (4.13); 135–140 
Mean of first 3 months, mM/L, mean (SD); IQR                                     137.57 (3.60); 135.3–139.8 
Difference before dialysis – mean of first 3 months, mM/L, mean (SD)                     0.09 (4.35) 
    Decrease >5 mM/L, n (%)                              63 (9.3) 
    Increase >5 mM/L, n (%)               62 (9.2) 
   
Figures denote serum sodium levels (mM/L). 
IQR, interquartile range. 
 
Table 3. Correlates of serum sodium levels before initiation of PD (preNa) 
 
 
Statistics by Spearman’s correlation coefficient. ANOVA (univariate) and multiple linear regression analysis (best models with Charlson’s score [Model 1] or diabetes and heart 
failure [Model 2]). First-order interaction terms not significant in multivariate analysis. Other variables not significant.  
PD, peritoneal dialysis; GFR, glomerular filtration rate; CRP, C-reactive protein.




Statistics by Spearman’s correlation coefficient. ANOVA (univariate) and multiple linear regression analysis (best models with Charlson’s score [Model 1] or diabetes and  
heart failure [Model 2]). First-order interaction terms not significant in multivariate analysis. 
Other variables not significant. PD, peritoneal dialysis; mNa, mean serum sodium; BMI, body mass index; GFR, glomerular filtration rate; CRP, C-reactive protein; 



















Table 5. Correlates of changes in serum sodium levels after initiation of PD 
 
 
Statistics by Spearman’s correlation coefficient. χ2 distribution (univariate) and multiple linear regression analysis. First-order interaction  terms not significant in multivariate analysis.  
Other variables not significant. PD, peritoneal dialysis; UF, ultrafiltration; PET, peritoneal equilibration test.
Table 6. Baseline predictors of mortality 
 
 
Statistics by Kaplan-Meier (log rank; univariate) and Cox’s regression (in bold, variables included in the best models). For univariate analysis (+) denotes direct and (–) denotes inverse  
correlation with mortality.  
Other variables not significant. First-order interaction terms with mNa significant for plasma albumin (p = 0.033), blood hemoglobin (p = 0.044), and GFR (p = 0.029; Model 1) and for  
CRP (p = 0.044) and GFR (p = 0.019; Model 2). Interaction terms for D/P creatinine (Model 1) p = 0.058 and for blood hemoglobin (Model 2) p = 0.066. 
HR, hazard ratio; GFR, glomerular filtration rate; CRP, C-reactive protein; RAAS, renin-angiotensin-aldosterone system; BMI, body mass index; UF, ultrafiltration; PET, peritoneal  
equilibration test; ECW/ICW, extracellular/intracellular water; BIA, bioimpedance analysis; PD, peritoneal dialysis; mNa, mean serum  sodium.
Analysis of Factors Modifying the Association between mNa and Outcome 
Stratified analysis after significant (or close to significance) interaction terms showed that mNa 
levels associated a risk of mortality in hypoalbuminemic (but not in normoalbuminemic) patients, 
as also in patients with higher (but not lower) levels of CRP, higher (but not lower) levels of RKF, 
lower (but not higher) levels of hemoglobin at inception of PD and faster (but not slower) than 
median D/Pcrea values (Fig. 2). In addition, the association between mNa and mortality was 
apparent only in patients using icodextrin for the long dwell and also those not treated with RAAS 
antagonists. Despite a patently lower statistical power (n = 180), our data also indicated that the 
association between mNa and mortality was more evident in patients less overhydrated or 
presenting lower than median lean body mass levels (Fig. 2). Finally, we observed minor, 
nonsignificant trends to a better correlation between mNa and mortality in women (p = 0.089 vs. p 
= 0.17 in males), malnourished patients (p = 0.091 vs. p = 0.19 in well-nourished patients), and in 
those treated with continuous ambulatory PD (p = 0.069 vs. p = 0.35 in patients on automated PD; 
Fig. 3). 
 
To characterize the relatively unexpected patterns of association between mNa and mortality 
according to GFR and the use of icodextrin-based solution, we analyzed the correlation between 
these 2 factors and the main variables scrutinized. As expected, GFR showed a direct correlation 
with plasma albumin (p < 0.001) and hemoglobin (p < 0.001) and an inverse correlation with CRP 
(p < 0.001). Diabetics (p = 0.005) presented higher levels of GFR, while the opposite was true for 
patients with malnutrition (p = 0.01) or a background of heart failure (p = 0.03). On the other hand, 
patients using icodextrin were more frequently diabetic (p < 0.001), had a slightly increased 
background of heart failure (p = 0.044), and presented  lower levels of GFR (p < 0.001) and 
plasma albumin (p < 0.001), faster peritoneal transport rates (p < 0.001), and slightly higher levels 
of CRP (p = 0.047). Regarding body composition analysis, we observed a limited correlation 
between a higher extracellular to intracellular water ratio, on one side and a lower GFR (p = 0.052) 
the use of icodextrin (p = 0.045) on the other. Finally, lean BMI levels were marginally higher in 
patients with better preserved GFR (p = 0.078). 
Discussion 
Hyponatremia is the electrolyte disorder most commonly diagnosed in clinical practice. It can 
be observed in many different clinical settings and its appearance, particularly if it develops 
acutely, is a recognized harbinger of poor prognosis [13]. The same contentions apply for patients 
at different stages of CKD [5, 14, 15], including those treated with hemodialysis [16–19]. The 
general pathogenesis of this disorder has been extensively investigated and is available for review 
elsewhere [20]. In the majority of cases, incapacity to regulate adequately water excretion 
underlies the appearance of this complication, either as the primary culprit or as an important 
contributor to the generation and persistence of the disorder. Less frequently, other mechanisms 
may be operative, including abnormal fluid intake rates, presence of osmotically active solutes in 
extracellular fluid, hypovolemic states, endocrinopathies, or adverse effects of some drugs. 
 
Patients with CKD retain their capacity to excrete excess water until advanced phases of the 
disorder [11].  As patients approach end-stage CKD, the ability to dilute and concentrate urine 
vanishes, and isosthenuria becomes the rule. At this point, the capacity of the organism to manage 
changes in osmolality declines, and the risk of hyponatremia increases [11, 12]. Among 
hemodialysis patients without significant RKF, hyponatremia is most frequently the consequence 
of a positive fluid balance (overhydration), but may also be secondary to accumulation of 
extracellular solutes (e.g., glucose) or transcellular shifts of intracellular solutes, a condition 
frequently linked to inflammatory and wasting states [12, 17]. In patients with significant GFR, 
inflammation may also contribute to hyponatremia by means of IL6-stimulated, nonosmotic 
secretion of vasopressin [21]. Loss of electrolytes, as observed in malnourished patients [22] or 
those presenting increased intestinal or peritoneal losses, represents a less common cause of 
hypovolemic hyponatremia, in patients on dialysis. 
 
Individuals undergoing chronic PD share most of the considerations in the preceding 
paragraph. A better preservation of GFR could help to prevent hypervolemia and, consequently, 
exert some protective effect against hyponatremia. However, bioimpedance-based surveys have 
shown than overhydration is very prevalent in these patients, even at PD inception [23]. On the 
other hand, PD may associate some other characteristics predisposing to hyponatremia, including 
hyperglycemia and excess peritoneal solute losses. Use of polyglucose-based solutions decreases 
plasma sodium concentration, seemingly due to water shifts secondary to the accumulation of 
metabolites of icodextrin [12]. The impact of the latter phenomenon is usually modest, but can be 
clinically significant in patients with other factors predisposing to hyponatremia [24]. 
 
Our study scrutinized serum sodium immediately before PD was started, which provided a 
reference to evaluate the effect of the introduction of this therapy. Comorbidity and GFR were 
independent predictors of both preNa and mNa levels (Tables 3, 4). Prescription of icodextrin was 
the only factor consistently modifying serum sodium after initiation of PD. Other studies have 
provided a rather inconsistent list of factors associated with hyponatremia in PD patients, 
including older age [9, 10], female gender [7, 8], ethnic background [8], diabetes [7, presence of 
markers of malnutrition and inflammation [12]. 
 
The common association of hyponatremia with different systemic conditions feeds the 
hypothesis that this complication may represent a marker rather than a pathogenic factor of 
mortality. Moderate chronic hyponatremia (serum Na > 130 mM/L) is usually well tolerated by 
patients with CKD. However, low serum Na has been shown to provoke organ and system 
dysfunctions, including neurologic and cognitive disorders [26], fracture risk, cardiac malfunction, 
and impaired immunity [12, 20, 25]. This question may be consequential because, if we accept a 
































Fig. 1. Survival of patients incident in PD according to the mean of serum sodium levels during the first 3 months  
of  therapy 
 
 
Fig. 2. Foster plot of the association between mNa levels and patient mortality after stratification of different study 
variables. Median of lean BMI 13.9 males vs. 12.1 (kg/m2) females. ECW, extracellular water; ICW, intracellular water; 
RAAS, renin-angiotensinaldosterone system; PET, peritoneal equilibration test; GFR, glomerular filtration rate; CRP, C-
reactive protein; BMI, body mass index. 
 
The reported association between hyponatremia and mortality is controversial, in patients 
undergoing PD. A relatively small size of previous studies may explain why some have been able 
to disclose such correlation [6, 7], which has not been observed by others [9, 10]. In the best 
powered study to date, Ravel et al. [8] disclosed significant associations between baseline and 
time-dependent sodium levels, on one side, and later survival of incident PD patients, on the other. 
Remarkably, the effect varied significantly in the different models applied, emphasizing the 
difficulties inherent to clarify the prognostic significance of hyponatremia. The study by Ravel et 
al. [8] scrutinized a wide array of control variables, but could not retrieve some relevant ones, 
including markers of volume overload, wasting, and inflammation. Moreover, GFR, an essential 
control variable in this setting, was also estimated from a relatively imprecise marker (renal urea 
Kt/V) [8]. 
Fig. 3. Foster plot of the association between mNa levels and patient mortality after stratification of demographic and 
clinical variables (differences not significant). Median of fat mass index 12.4 males vs. 13.1 (kg/m2) females. BMI, body 
mass index; UF, ultrafiltration; PET, peritoneal equilibration test; PD, peritoneal dialysis; CAPD, continuous ambulatory 







Our results side with previous studies disclosing a significant correlation between serum 
sodium, on one side, and survival on PD, on the other (Table 6). However, our main objective was 
to define how this association can differ, according to the putatively dominant factors generating 
hyponatremia in these patients, namely, overhydration wasting/inflammatory states, and adverse 
effects of drugs and dialysis prescription. For this purpose, we used stratified analyses (Fig. 2, 3). 
Our results suggest that hyponatremia predicts mortality mainly in individuals with a background 
of inflammation and wasting, as shown by direct (elevated CRP protein, lower lean body mass) 
and indirect (low plasma albumin, low blood hemoglobin, faster peritoneal transport rates, no 
treatment with RAAS antagonists) markers of this condition. On the contrary, this association was 
less apparent in settings of mere volume overload (imbalance between fluid intake and removal), 
which should not be unexpected, because overhydration is a treatable condition. In fact, mNa was 
a predictor of mortality in patients with lesser degrees of overhydration by body composition 
analysis, despite the limited number of cases scrutinized (n = 180; Fig. 2). On the other hand, the 
mode of influence of GFR on the association between mNa and mortality deserves some comment. 
On average, patients with higher levels of GFR were less overhydrated, presented less 
inflammatory features, and were better nourished than their counterparts with lower GFR levels. 
Our hypothesis is that, in this subset of lower risk of wasting and overhydration, hyponatremia 
may mark more accurately individuals with particularly poor clinical patterns (including ongoing 
wasting) demanding an early initiation of renal replacement therapy. The significance of the 
differing association between mNa and mortality according to the use of icodextrin to diabetics 
and patients with lower levels of GFR and a limited capacity of ultrafiltration. These 
characteristics may match better with the risk of overhydration than with the presence of 
inflammatory features. However, prescription of this solution aims to prevent overhydration, and 
is expected to be efficient for this purpose, in a majority of cases. The scenery is further 
compounded by the particular effect of icodextrin on serum sodium levels (Table 5). Overall, the 
significance of these findings is unclear, and confounding cannot be excluded. 
 
Generic estimators of malnutrition (including subjective global assessment and BMI) did not 
exert a clear differential impact on the prognostic significance of hyponatremia, in our study. 
However, the accuracy of these markers may be confounded by factors such as fat accumulation or 
overhydration. This limitation may have been aggravated by the relatively low proportion of 
patients suffering malnutrition (and particularly, severe malnutrition), in our population (Table 1). 
Remarkably, only 16 of our patients (2.2%) presented a BMI < 18 kg/m2. A previous, more 
powered analysis [8] disclosed a limited influence of muscle mass (estimated from serum 
creatinine) on the pattern of association between serum sodium and patient survival. 
 
Our study suffers some significant limitations, including its retrospective, single-center design. 
The sample was relatively large, but may still have been underpowered to scrutinize the effects of 
some variables. Only 180 patients had a body composition analysis, and the capacity of 
ultrafiltration was estimated in a standardized way in 241 cases. Among the strengths of the study, 
we should remark the availability of markers of the 3 main conditions resulting in hyponatremia in 
PD patients, as also the clarity of the results, well supported by the data presented. 
 
In conclusion, our results suggest that hyponatremia performs as a consistent correlate of the 
risk of mortality in PD patients presenting direct or indirect markers of an underlying wasting 
and/or inflammatory state. On the contrary, this association is not apparently linked to the presence 
of mere overhydration, nominal preexisting comorbid conditions, or treatment with loop diuretics 
or psychotropic drugs. Our findings may provide some support to those contending that, among 
PD patients, chronic, moderate hyponatremia performs as a marker of the overall risk of mortality 
rather than as a direct pathogenic factor. Further studies will be necessary to confirm the findings 
of this single-center analysis. 
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